Acumen Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Amortized Cost
Acumen Pharmaceuticals, Inc. (ABOS) had Debt Securities, Available-for-sale, Amortized Cost of $89.11 million as of 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Notes › Credit Losses › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-03-26
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $89.11M.
- 2025-06-30: Debt Securities, Available-for-sale, Amortized Cost $129.33M.
- 2025-03-31: Debt Securities, Available-for-sale, Amortized Cost $167.77M.
- 2024-12-31: Debt Securities, Available-for-sale, Amortized Cost $195.95M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2025-09-30 | $89.11M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $129.33M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $167.77M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $195.95M 10-K · filed 2026-03-26 |
| 2024-09-30 | $225.19M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $213.59M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $249.84M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $238.88M 10-K · filed 2025-03-27 |
| 2023-09-30 | $188.30M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $95.59M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $106.35M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $64.09M 10-K · filed 2024-03-26 |
| 2021-12-31 | $103.92M 10-K · filed 2023-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |